Wow - quite an amazing benefit conferred with this new shortened timeframe.
I wonder if that changes things for us? I know that JP has talked in investment seminars and webinars after company announcements about the option to progress to a pharma that sells, but he has always seemed quite dismissive. He has said if shareholders wanted it, they company would consider it but it did not seem genuine.
I could be totally wrong but I sensed a slightly different appetite in his interview with Alan Kohler recently and this news might further change the mind or at least provide pause for thought.
Ann: Priority Review Voucher sale proceeds received, page-16
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |